RESUMEN

In 2005-2007, primary drug resistance of Mycobacterium tuberculosis (MBT) was studied in 1318 patients with new-onset destructive pulmonary tuberculosis. This was identified in 31.8, 28.5, and 29.1% in 2005, 2006, and 2007, respectively. During these years, there was an increase in the primary rifampicin resistance of MBT from 28.8% in 2005 to 37.7% in 2007. Primary streptomycin resistance was 100% in 2007. The authors consider the primary resistance of MBT as a priority problem of phthisiology.

Asunto(s)

Antituberculosos/uso terapéutico , Mycobacterium tuberculosis/efectos de los fármacos , Tuberculosis Resistente a Múltiples Medicamentos/tratamiento farmacológico , Tuberculosis Pulmonar/tratamiento farmacológico , Estudios de Seguimiento , Humanos , Mycobacterium tuberculosis/aislamiento & purificación , Pronóstico , Estudios Retrospectivos , Tuberculosis Resistente a Múltiples Medicamentos/microbiología , Tuberculosis Pulmonar/microbiología